Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

IMUC Wrap-Up

|Includes:ImmunoCellular Therapeutics, Ltd. (IMUC)

Just a quick note after listening to the IMUC call, most everything was unchanged and re-iterated. The trial is still running and that is very good. There has been concern and confusion about when and if the company will announce when the trial is complete, and we got clarity:

The company will *not* announce when they learn that the trial has ended, BUT within 72 hours of receiving top line results they will share those results in a press release. That time lag should not be too long, my guess is a week or two based on the CEO's past comments on verifying that they have in fact had 64 events.

So that is good, IMO opinion no news can be taken as good news minus a fortnight.

Other news:

  • filed for EU Orphan status
  • ICT-121 has begun phase I trial and will start enrolling shortly
  • inbound and outbound strategy - looking at in-licensing more products and forming alliances to market ICT-107 outside of the US, having global "exploratory discussions"

They talked about plenty of other things but mostly they repeated and re-iterated positions already taken. Overall a very good call, the trial is good news and we know what to expect.

Disclosure: I am long IMUC.

Stocks: IMUC